Rep. Jefferson Shreve Sells Off Shares of AbbVie Inc. (NYSE:ABBV)

Representative Jefferson Shreve (R-Indiana) recently sold shares of AbbVie Inc. NYSE: ABBV. In a filing disclosed on May 08th, the Representative disclosed that they had sold between $50,001 and $100,000 in AbbVie stock on April 17th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

• Purchased $50,001 - $100,000 in shares of Chipotle Mexican Grill NYSE: CMG on 4/17/2025.
• Purchased $50,001 - $100,000 in shares of Applied Materials NASDAQ: AMAT on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Caterpillar NYSE: CAT on 4/17/2025.
• Sold $15,001 - $50,000 in shares of Lululemon Athletica NASDAQ: LULU on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Western Digital NASDAQ: WDC on 4/17/2025.
• Sold $15,001 - $50,000 in shares of Zoetis NYSE: ZTS on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Stryker NYSE: SYK on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of NextEra Energy NYSE: NEE on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of CSX NASDAQ: CSX on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Ross Stores NASDAQ: ROST on 4/17/2025.

AbbVie Price Performance

Shares of NYSE:ABBV traded down $1.28 on Friday, hitting $184.30. The company had a trading volume of 7,806,084 shares, compared to its average volume of 6,133,352. The company has a market cap of $326.02 billion, a PE ratio of 76.79, a PEG ratio of 1.62 and a beta of 0.56. The business has a 50 day moving average of $194.23 and a 200 day moving average of $187.21. AbbVie Inc. has a 52-week low of $153.58 and a 52-week high of $218.66. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Friday, April 25th. The company reported $2.46 EPS for the quarter, topping analysts' consensus estimates of $2.40 by $0.06. The business had revenue of $13.34 billion during the quarter, compared to the consensus estimate of $12.91 billion. AbbVie had a net margin of 7.59% and a return on equity of 296.28%. The company's quarterly revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.31 earnings per share. As a group, equities analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be issued a $1.64 dividend. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.56%. AbbVie's dividend payout ratio (DPR) is 279.15%.

Insider Transactions at AbbVie

In other news, EVP Perry C. Siatis sold 5,778 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $197.90, for a total transaction of $1,143,466.20. Following the completion of the transaction, the executive vice president now directly owns 22,381 shares of the company's stock, valued at approximately $4,429,199.90. This represents a 20.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jeffrey Ryan Stewart sold 58,832 shares of the business's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $210.08, for a total value of $12,359,426.56. Following the transaction, the executive vice president now owns 53,234 shares of the company's stock, valued at $11,183,398.72. This represents a 52.50 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 113,471 shares of company stock valued at $23,426,451. Insiders own 0.08% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ABBV shares. Wells Fargo & Company raised their price objective on AbbVie from $210.00 to $240.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Morgan Stanley raised their price target on AbbVie from $241.00 to $250.00 and gave the stock an "overweight" rating in a research note on Monday, April 28th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $194.00 price objective on shares of AbbVie in a research note on Tuesday, April 8th. Raymond James reissued an "outperform" rating and issued a $220.00 target price (up from $218.00) on shares of AbbVie in a research report on Monday, February 3rd. Finally, UBS Group upped their price target on shares of AbbVie from $181.00 to $190.00 and gave the stock a "neutral" rating in a research report on Monday, February 3rd. Seven investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and four have given a strong buy rating to the company's stock. According to data from MarketBeat.com, AbbVie currently has a consensus rating of "Moderate Buy" and an average target price of $211.41.

Institutional Investors Weigh In On AbbVie

A number of large investors have recently added to or reduced their stakes in the company. Blue Bell Private Wealth Management LLC grew its stake in AbbVie by 30.4% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 223 shares of the company's stock valued at $40,000 after purchasing an additional 52 shares in the last quarter. Steel Grove Capital Advisors LLC increased its stake in shares of AbbVie by 1.7% in the fourth quarter. Steel Grove Capital Advisors LLC now owns 3,110 shares of the company's stock worth $553,000 after buying an additional 52 shares during the last quarter. Peninsula Wealth LLC raised its holdings in AbbVie by 4.1% in the fourth quarter. Peninsula Wealth LLC now owns 1,360 shares of the company's stock valued at $242,000 after acquiring an additional 54 shares in the last quarter. Private Management Group Inc. boosted its stake in AbbVie by 1.9% during the 1st quarter. Private Management Group Inc. now owns 2,938 shares of the company's stock valued at $616,000 after acquiring an additional 54 shares during the last quarter. Finally, Physicians Financial Services Inc. grew its holdings in AbbVie by 0.5% during the 4th quarter. Physicians Financial Services Inc. now owns 12,150 shares of the company's stock worth $2,159,000 after acquiring an additional 55 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.